Amerise Biosciences Ltd
₹ 0.84
0.00%
21 Sep
- close price
About
Incorporated in 1984, Amerise Biosciences Ltd specializes in NDA, 505(b)(2), and complex
formulations.[1]
Key Points
- Market Cap ₹ 5.55 Cr.
- Current Price ₹ 0.84
- High / Low ₹ 1.03 / 0.50
- Stock P/E
- Book Value ₹ 0.82
- Dividend Yield 0.00 %
- ROCE 0.37 %
- ROE 0.37 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
- Stock is trading at 1.03 times its book value
Cons
- Company has low interest coverage ratio.
- Company has a low return on equity of -0.74% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Industrials Capital Goods Industrial Products Plastic Products - Industrial
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00 | 0.00 | 0.00 | 1.18 | 0.00 | 0.00 | 9.58 | 0.01 | 0.04 | 0.00 | 0.00 | 0.19 | |
| 0.05 | 0.03 | 0.94 | 0.02 | 1.18 | 0.15 | 0.17 | 9.03 | 0.13 | 0.19 | 0.18 | 0.24 | 0.24 | |
| Operating Profit | -0.05 | -0.03 | -0.94 | -0.02 | 0.00 | -0.15 | -0.17 | 0.55 | -0.12 | -0.15 | -0.18 | -0.24 | -0.05 |
| OPM % | 0.00% | 5.74% | -1,200.00% | -375.00% | 5.26% | 7.69% | -26.32% | ||||||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.17 | 0.00 | 0.00 | 0.00 | 0.19 | 0.26 | 0.00 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.05 | -0.03 | -0.94 | -0.02 | 0.00 | -0.15 | -0.34 | 0.55 | -0.12 | -0.15 | 0.01 | 0.02 | -0.05 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||
| -0.05 | -0.03 | -0.94 | -0.02 | 0.00 | -0.15 | -0.34 | 0.55 | -0.12 | -0.15 | 0.01 | 0.02 | -0.05 | |
| EPS in Rs | -0.01 | -0.00 | -0.14 | -0.00 | 0.00 | -0.02 | -0.05 | 0.08 | -0.02 | -0.02 | 0.00 | 0.00 | -0.01 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -24% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 16% |
| 3 Years: | 29% |
| TTM: | -200% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -5% |
| 5 Years: | -15% |
| 3 Years: | 9% |
| 1 Year: | 20% |
| Return on Equity | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | 1% |
| 3 Years: | -1% |
| Last Year: | 0% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 |
| Reserves | -0.05 | -0.07 | -1.01 | -1.03 | -1.03 | -1.18 | -1.52 | -0.97 | -1.09 | -1.23 | -1.23 | -1.21 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.09 | 0.00 | 0.00 | 0.00 | |
| 0.00 | 0.00 | 0.04 | 0.01 | 0.02 | 0.60 | 0.54 | 6.27 | 0.04 | 0.01 | 3.08 | 2.03 | |
| Total Liabilities | 6.56 | 6.54 | 5.64 | 5.59 | 5.60 | 6.03 | 5.63 | 11.99 | 5.65 | 5.39 | 8.46 | 7.43 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 4.82 | 5.89 | 2.34 | 2.31 | 0.54 | 5.37 | 3.04 | 4.69 | 4.57 | 2.27 | 2.38 | 3.77 |
| 1.74 | 0.65 | 3.30 | 3.28 | 5.06 | 0.66 | 2.59 | 7.30 | 1.08 | 3.12 | 6.08 | 3.66 | |
| Total Assets | 6.56 | 6.54 | 5.64 | 5.59 | 5.60 | 6.03 | 5.63 | 11.99 | 5.65 | 5.39 | 8.46 | 7.43 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.27 | 1.08 | -3.56 | -0.04 | -1.78 | 4.89 | -0.39 | 0.06 | -0.13 | -0.17 | 3.07 | -1.06 | |
| 0.32 | -1.07 | 3.55 | 0.03 | 1.77 | -4.89 | 0.39 | -0.15 | 0.13 | 0.27 | -3.07 | 1.63 | |
| -0.59 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.01 | -0.09 | 0.00 | 0.00 | |
| Net Cash Flow | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 | 0.01 | -0.01 | -0.01 | 0.00 | 0.01 | 0.00 | 0.57 |
| Free Cash Flow | 0.27 | 1.08 | -3.56 | -0.04 | -1.78 | 4.89 | -0.39 | 0.06 | -0.13 | -0.17 | 3.07 | -1.06 |
| CFO/OP | -540% | -3,600% | 379% | 200% | -3,260% | 229% | 11% | 108% | 113% | -1,706% | 442% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 1,382.67 | 236.98 | 0.00 | 0.00 | ||||||||
| Inventory Days | 0.00 | 0.00 | ||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 1,382.67 | 236.98 | 0.00 | 0.00 | ||||||||
| Working Capital Days | 1,376.48 | -1.91 | -1,460.00 | -182.50 | ||||||||
| ROCE % | -0.73% | -0.46% | -15.49% | -0.36% | 0.00% | -2.72% | -6.46% | 10.18% | -2.12% | -2.73% | 0.19% | 0.37% |
Documents
Announcements
-
Closure of Trading Window
- Trading window closed from 1 Oct 2026 until 48 hours after Q2 FY26 results.
- Reg. 34 (1) Annual Report.
- Intimation Of Book Closure Pursuant To Regulation 42 Of The SEBI (LODR) Regulations, 2015.
- Submission Of Notice Of Annual General Meeting Under Regulation 30 Of The SEBI (LODR) Regulations, 2015
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Overview:[1]
ABL is an integrated pharmaceutical company specializing in NDA, 505(b)(2), and complex formulations. Its core expertise spans the development of injectables, ophthalmic,
and oral dosage forms, offering end‑to‑
end capabilities from concept to clinic.
The company provides regulatory‑compliant support for 505(b)(2) products and generic filings, including pre‑IND meetings with the
FDA, IND‑enabling studies, product registration, and clinical service management.